Hormone-dependent prostate cancer
RecruitingA study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.
A study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.
- Disease:Hormone-dependent prostate cancer
- Substances:Lutetium (177LU) vipivotide tetraxetan
Germany- Participants:18–64 years · 65+ years
- Substances:Lutetium (177LU) vipivotide tetraxetan
- Sponsor:University College London


